Rittenberg L, Morrissey D, El-Khawand D et al: Kenalog injection into hunner's lesions as a treatment for interstitial cystitis/bladder pain syndrome
These findings may help inform how HR teams view GLP-1 coverage going forward, said Farheen Dam, Aons head of health for North America
Be prepared to discuss your weight history, previous treatments, family history of diabetes or metabolic conditions, and any prior experiences with GLP-1 or GIP agonists
With patents for semaglutide and other GLP-1 drugs set to expire in key markets, Indian CDMOs, API makers, and biologics experts are well placed to step in
Stockouts are a big problem in terms of access and, according to Ruder, have been fuelled by patients who are not diabetic or classified as obese or overweight, pressuring clinicians to prescribe Ozempic in particular for vanity or cosmetic or simply aesthetic purposes